There is a growing need for precision antibacterials and antibiotics. PrecisioBiotix is creating best-in-class and first-in-class biological solutions to address this need.  The company has a large portfolio of precision antibacterial assets and technologies held in two separate corporate entities: Lysigen and Phagelux.

Lysigen is located in China and is creating best-in-class and first-in-class lysins. Lysins are hydrolytic enzymes that cleave a bacteria wall thereby efficiently killing the bacteria. As compared to chemical antibacterials, lysins have the following advantages: more rapid, targeted, safer (do not harm non-targeted biome), can penetrate biofilm, and cause no bacterial resistance.

Phagelux is located in Canada.  It is creating bacteriophage products.  The lead product is a clinical stage product called Bactelide^TM. This product is a phage cocktail encapsulated in a sustained released biodegradable micro polymer.  It is designed to prevent and treat topical AMR infections. In addition, as compared to the existing standard of care, it improves wound healing times. 

Lysigen and Phagelux have an emphasis on topical solutions. Both Lysigen and Phagelux are led by globally leading scientists in their respective fields.